AI

Isomorphic Labs raises $5 billion Series C to push AI-designed drugs toward human trials

Alphabet's drug design unit has secured the largest venture round in biotech history, but its most advanced molecules have still not entered human testing.

T
By TechQuire Daily Staff TechQuire Daily Staff
November 17, 2026 / 7 min read

Isomorphic Labs, the drug design company that Alphabet spun out of Google DeepMind in 2021, has spent five years arguing that medicines can be designed on a computer before they are ever made in a laboratory. On November 17 the company put a price on that argument, announcing a $5 billion Series C round that it described as oversubscribed. The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor and Alphabet investing again.

The raise lands roughly six months after a $2.1 billion Series B in May and about eight times the size of the $600 million first external round the company took in March 2025. R&D World, citing BioSpace, called it the largest venture round in biotech history, surpassing the $3 billion that Altos Labs raised at its 2022 launch. Isomorphic declined to share its valuation, leaving outsiders to work from Bloomberg's November 4 report that the company was in talks to raise at roughly $50 billion.

The company sits at an unusual intersection. Its scientific lineage runs back to AlphaFold, the protein structure prediction system that earned Demis Hassabis and John Jumper the Nobel Prize in chemistry. Its commercial structure runs back to Alphabet, which holds 75 percent or more of its shares and voting rights according to UK Companies House records reflecting a June share allotment. And its chief executive now works on medicine full time: Hassabis stepped down as chief executive of Google DeepMind in August to become its chairman and Alphabet's chief scientist, three and a half months before this round was announced.

What Isomorphic has not yet done is put a molecule of its own design into a human being. Its programs remain preclinical, and no AI-designed drug has ever received regulatory approval. That gap between capital raised and evidence generated is the real story of the round.

Key Facts

Reuters reported on November 17 that Isomorphic raised $5 billion in a Series C co-led by Greenoaks and Sequoia Capital, and that the company declined to share its valuation. CNBC reported on November 17 that the round arrived three and a half months after Hassabis stepped back as DeepMind's chief executive, and that drug discovery startups have raised a record $23.2 billion in 2026 according to Dealroom.

TechCrunch reported on November 17 that all existing backers participated, including Alphabet's venture arms GV and CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. The company's own announcement on November 17 confirmed the same list and added that Alphabet made a continued significant investment. R&D World noted the same day that the financing more than doubles the May Series B and that BioSpace counts at least $7.7 billion raised by Isomorphic since March 2025.

The proceeds are earmarked for IsoDDE, the proprietary drug design engine that unifies a suite of foundational simulation models working across multiple therapeutic areas and drug modalities. The company says IsoDDE explores vast chemical spaces to design, refine and deliver engineered molecules with drug-like properties, and that proprietary agents reason over complex biological systems to turn those models into a multi-modality pipeline. Money will also go toward expanding into new biology, building a partner ecosystem and constructing what the release calls scalable AI-first translational and clinical development infrastructure as candidates move toward trials.

Isomorphic says it has more than 20 internal programs underway and has reported positive preclinical results in oncology and immunology, both internally and with partners, which it describes as setting the stage for clinical entry. It lists Novartis, Eli Lilly and Johnson & Johnson as partners. President Max Jaderberg said teams are routinely solving complex biological problems that have stalled traditional research for decades. Greenoaks founder Neil Mehta and Sequoia partner Konstantine Buhler both issued statements alongside the announcement.

Reuters reported on November 17 that the company was spun out of Google DeepMind in 2021. Isomorphic said in its own release that it is headquartered in London with offices in Cambridge, Massachusetts and Lausanne, Switzerland, and that it is led by chief executive Sir Demis Hassabis and Jaderberg. The company described the round as oversubscribed but did not attach a valuation, a headcount or a revenue figure to it.

Analysis

What this really means is that the market has stopped pricing AI drug discovery on demo quality and started pricing it on pipeline proximity to the clinic. A $5 billion round against a reported $50 billion valuation implies investors expect Isomorphic's candidates to reach trials on a schedule the company has already moved once. Hassabis said at Davos in January that first clinical trials were expected by the end of 2026, a target that replaced an earlier end of 2025 goal. A round of this size gives the company room to miss that date without running out of money, which is precisely what it buys.

The investor roster tells a second story. Returning capital from Thrive, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund, plus a fresh check from Andreessen Horowitz, means the existing syndicate did not merely hold its position but enlarged it. Reuters reported on November 17 that Alphabet made a significant investment. When the controlling shareholder and every prior backer re-up in the same round, the signal is less about new conviction than about the cost of being underweight if the technology works.

The bigger picture here is that Isomorphic is deliberately not a platform company in the usual sense. Jaderberg said at Bloomberg Tech in London on November 2 that the company is not selling access to the models, not selling tokens and not selling API access. It described IsoDDE in a February technical report without code, weights or training details, and has said it does not plan to reveal the secret sauce. That is the opposite of how DeepMind handled early AlphaFold generations, and it concentrates Isomorphic's value in molecules and partnerships rather than in licensing revenue.

The competitive backdrop complicates the story. CNBC reported on November 17 that Anthropic announced an AI drug discovery program in June and that OpenAI partnered with Novo Nordisk in April. McKinsey reported in September that investor funding for AI-enabled drug discovery more than doubled from $4.1 billion in 2023 to $8.4 billion in 2025. Record totals do not distinguish between companies holding preclinical packages and companies holding slide decks, and Dealroom's $23.2 billion for 2026 is a category number rather than a quality signal.

Why It Matters

The size of this round sets a benchmark the rest of the sector will be measured against whether or not the science justifies it. If Isomorphic converts IsoDDE output into an investigational new drug filing in the near term, the reported $50 billion valuation will look conservative and the preclinical discount applied to every competitor will compress. If the first programs slip again, the same round becomes the clearest evidence that capital in this category has outrun clinical proof.

There is also a structural question about concentration. Alphabet already holds 75 percent or more of the shares and voting rights and has now invested again alongside outside capital. Isomorphic is therefore a rare case of a venture-scale biotech whose controlling shareholder is a public technology company with its own balance sheet and its own AI labs. Any future decision about spinning it out, licensing its engine or advancing a program alone runs through that relationship.

The scientific stakes are equally concrete. AlphaFold changed how structural biology is done, but predicting a protein's shape is not the same as producing a molecule that survives a clinical trial. Isomorphic's claim is that its models have narrowed that gap enough to justify industrial scale spending. That claim is now funded well enough to be tested rather than debated, which is more than can be said for most AI claims in medicine.

Next Up

The immediate test is clinical entry. Hassabis said the round enables the company to accelerate its therapeutic programs toward trials to deliver tangible impact for patients. Watch for an investigational new drug filing or a first in human study, and watch whether the first program comes from oncology or immunology, the two areas where Isomorphic has reported positive preclinical data.

Beyond that, the company has said it will expand into new biology and build clinical development infrastructure, which points to hiring and site buildout in London, Cambridge and Lausanne before any product revenue appears. With at least $7.7 billion raised since March 2025 and nothing approved, the next twelve months will decide whether the largest venture round in biotech history becomes the template for AI-designed medicine or the clearest example of a valuation that arrived before the data.

Tagged

Comments (0)

No comments yet. Be the first to share your thoughts.